Another study using mouse models has shown that a combination of MEK and CDK4/6 inhibitors induces RB-mediated senescence to produce a SASP that includes pro-angiogenic factors that promote tumor vascularization, which in turn enhances drug delivery and the efficacy of cytotoxic gemcitabine chemotherapy. The gene discussed is MAP2K7; the disease is neoplasm.